{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T22:37:25Z","timestamp":1778711845443,"version":"3.51.4"},"reference-count":66,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Hematology\/Oncology Clinics of North America"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1016\/j.hoc.2020.06.012","type":"journal-article","created":{"date-parts":[[2020,8,5]],"date-time":"2020-08-05T08:02:14Z","timestamp":1596614534000},"page":"983-996","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Key Clinical and Translational Research Questions to Address Unmet Needs in Mantle Cell Lymphoma"],"prefix":"10.1016","volume":"34","author":[{"suffix":"Jr.","given":"Thomas D.","family":"Rodgers","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan W.","family":"Friedberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.hoc.2020.06.012_bib1","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1200\/JCO.2008.16.8435","article-title":"Improvement of overall survival in advanced stage mantle cell lymphoma","volume":"27","author":"Herrmann","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2020.06.012_bib2","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1200\/JCO.2008.19.6121","article-title":"Outcome of deferred initial therapy in mantle-cell lymphoma","volume":"27","author":"Martin","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2020.06.012_bib3","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1002\/cncr.23608","article-title":"Incidence trends of mantle cell lymphoma in the United States between 1992 and 2004","volume":"113","author":"Zhou","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.hoc.2020.06.012_bib4","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1093\/jnci\/djk152","article-title":"Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis","volume":"99","author":"Schulz","year":"2007","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.hoc.2020.06.012_bib5","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1200\/JCO.1998.16.1.13","article-title":"High-dose chemoradiotherapy and anti-B-cell monoclonal antibody-purged autologous bone marrow transplantation in mantle-cell lymphoma: no evidence for long-term remission","volume":"16","author":"Freedman","year":"1998","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2020.06.012_bib6","doi-asserted-by":"crossref","first-page":"2944","DOI":"10.1182\/blood-2013-11-531327","article-title":"Randomized trial of bendamustine-rituximab or R-CHOP\/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study","volume":"123","author":"Flinn","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2020.06.012_bib7","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/S0140-6736(12)61763-2","article-title":"Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial","volume":"381","author":"Rummel","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.hoc.2020.06.012_bib8","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1182\/blood.V112.11.769.769","article-title":"Early consolidation with myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission in mantle cell lymphoma: long term follow up of a randomized trial of the European MCL Network","volume":"112","author":"Dreyling","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2020.06.012_bib9","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/bjh.13929","article-title":"A\u00a0phase 2 study of rituximab-bendamustine and rituximab-cytarabine for transplant-eligible patients with mantle cell lymphoma","volume":"173","author":"Armand","year":"2016","journal-title":"Br J Haematol"},{"key":"10.1016\/j.hoc.2020.06.012_bib10","doi-asserted-by":"crossref","first-page":"3803","DOI":"10.1200\/JCO.1998.16.12.3803","article-title":"Hyper-CVAD and high-dose methotrexate\/cytarabine followed by stem-cell transplantation: an active regimen for aggressive mantle-cell lymphoma","volume":"16","author":"Khouri","year":"1998","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2020.06.012_bib11","doi-asserted-by":"crossref","first-page":"7013","DOI":"10.1200\/JCO.2005.01.1825","article-title":"High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine","volume":"23","author":"Romaguera","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2020.06.012_bib12","doi-asserted-by":"crossref","first-page":"2687","DOI":"10.1182\/blood-2008-03-147025","article-title":"Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in\u00a0vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group","volume":"112","author":"Geisler","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2020.06.012_bib13","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1111\/bjh.14241","article-title":"15-year follow-up of the second Nordic mantle cell lymphoma trial (MCL2): prolonged remissions without survival plateau","volume":"175","author":"Eskelund","year":"2016","journal-title":"Br J Haematol"},{"key":"10.1016\/j.hoc.2020.06.012_bib14","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1111\/bjh.13796","article-title":"Rituximab plus hyper-CVAD alternating with MTX\/Ara-C in patients with newly diagnosed mantle cell lymphoma: 15-year follow-up of a phase II study from the MD Anderson Cancer Center","volume":"172","author":"Chihara","year":"2016","journal-title":"Br J Haematol"},{"key":"10.1016\/j.hoc.2020.06.012_bib15","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S0140-6736(16)00739-X","volume":"388","author":"Hermine","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.hoc.2020.06.012_bib16","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1111\/bjh.14480","article-title":"RB but not R-HCVAD is a feasible induction regimen prior to auto-HCT in frontline MCL: results of SWOG Study S1106","volume":"176","author":"Chen","year":"2017","journal-title":"Br J Haematol"},{"key":"10.1016\/j.hoc.2020.06.012_bib17","doi-asserted-by":"crossref","first-page":"3132","DOI":"10.1182\/bloodadvances.2019000526","article-title":"Five-year outcomes of the S1106 study of R-hyper-CVAD vs R-bendamustine in transplant-eligible patients with mantle cell lymphoma","volume":"3","author":"Kamdar","year":"2019","journal-title":"Blood Adv"},{"key":"10.1016\/j.hoc.2020.06.012_bib18","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1056\/NEJMoa1505237","article-title":"Lenalidomide plus rituximab as initial treatment for mantle-cell lymphoma","volume":"373","author":"Ruan","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.hoc.2020.06.012_bib19","doi-asserted-by":"crossref","first-page":"2016","DOI":"10.1182\/blood-2018-07-859769","article-title":"Five-year follow-up of lenalidomide plus rituximab as initial treatment of mantle cell lymphoma","volume":"132","author":"Ruan","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2020.06.012_bib20","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1182\/blood-2019-125681","article-title":"Ibrutinib, venetoclax plus obinutuzumab in newly diagnosed mantle cell lymphoma patients","volume":"134","author":"Le Gouill","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2020.06.012_bib21","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1182\/blood-2019-129323","article-title":"Minimal residual disease (MRD) assessment in the ECOG1411 randomized phase 2 trial of front-line bendamustine-rituximab (BR)-based induction followed by rituximab (R) \u00b1 lenalidomide (L) consolidation for mantle cell lymphoma (MCL)","volume":"134","author":"Smith","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2020.06.012_bib22","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1182\/blood-2004-10-3883","volume":"105","author":"Dreyling","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2020.06.012_bib23","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1200\/JCO.18.00690","article-title":"Survival outcomes of younger patients with mantle cell lymphoma treated in the rituximab era","volume":"37","author":"Gerson","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2020.06.012_bib24","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1182\/blood-2005-07-2845","article-title":"Quantitative assessment of molecular remission after high-dose therapy with autologous stem cell transplantation predicts long-term remission in mantle cell lymphoma","volume":"107","author":"Pott","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2020.06.012_bib25","doi-asserted-by":"crossref","first-page":"579","DOI":"10.3324\/haematol.2011.050203","article-title":"Detection of minimal residual disease following induction immunochemotherapy predicts progression free survival in mantle cell lymphoma: final results of CALGB 59909","volume":"97","author":"Liu","year":"2012","journal-title":"Haematologica"},{"key":"10.1016\/j.hoc.2020.06.012_bib26","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.bbmt.2016.12.634","article-title":"Molecular monitoring after autologous stem cell transplantation and preemptive rituximab treatment of molecular relapse; results from the Nordic mantle cell lymphoma studies (MCL2 and MCL3) with median follow-up of 8.5 years","volume":"23","author":"Kolstad","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.hoc.2020.06.012_bib27","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1056\/NEJMoa1701769","article-title":"Rituximab after autologous stem-cell transplantation in mantle-cell lymphoma","volume":"377","author":"Le Gouill","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.hoc.2020.06.012_bib28","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.bbmt.2015.08.035","article-title":"Pretransplantation minimal residual disease predicts survival in patients with mantle cell lymphoma undergoing autologous stem cell transplantation in complete remission","volume":"22","author":"Cowan","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.hoc.2020.06.012_bib29","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1093\/annonc\/mdn656","article-title":"Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study","volume":"20","author":"Goy","year":"2009","journal-title":"Ann Oncol"},{"key":"10.1016\/j.hoc.2020.06.012_bib30","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S1470-2045(15)00559-8","article-title":"Lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma (MCL-002; SPRINT): a phase 2, randomised, multicentre trial","volume":"17","author":"Trneny","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.hoc.2020.06.012_bib31","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/S0140-6736(15)00667-4","article-title":"Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study","volume":"387","author":"Dreyling","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.hoc.2020.06.012_bib32","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/S0140-6736(17)33108-2","article-title":"Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial","volume":"391","author":"Wang","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.hoc.2020.06.012_bib33","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1182\/blood-2018-99-117956","article-title":"Safety and activity of the investigational Bruton tyrosine kinase inhibitor zanubrutinib (BGB-3111) in patients with mantle cell lymphoma from a phase 2 trial","volume":"132","author":"Song","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2020.06.012_bib34","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1182\/blood-2015-10-673145","article-title":"Postibrutinib outcomes in patients with mantle cell lymphoma","volume":"127","author":"Martin","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2020.06.012_bib35","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1200\/JCO.2013.49.2454","article-title":"Autologous or reduced-intensity conditioning allogeneic hematopoietic cell transplantation for chemotherapy-sensitive mantle-cell lymphoma: analysis of transplantation timing and modality","volume":"32","author":"Fenske","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2020.06.012_bib36","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1177\/2040620714561579","article-title":"Mantle cell lymphoma: observation to transplantation","volume":"6","author":"Rajabi","year":"2015","journal-title":"Ther Adv Hematol"},{"key":"10.1016\/j.hoc.2020.06.012_bib37","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.hoc.2020.06.012_bib38","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.hoc.2020.06.012_bib39","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1182\/blood-2019-126064","article-title":"KTE-X19, an anti-CD19 chimeric antigen receptor (CAR) T\u00a0cell therapy, in patients (Pts) with relapsed\/refractory (R\/R) mantle cell lymphoma (MCL): results of the phase 2 ZUMA-2 study","volume":"134","author":"Wang","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2020.06.012_bib40","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1002\/hon.96_2629","article-title":"CD19-directed car T\u00a0cell therapy (CTL019) for relapsed\/refractory diffuse large B-cell and follicular lymphomas: four year outcomes","volume":"37","author":"Chong","year":"2019","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.hoc.2020.06.012_bib41","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1182\/blood-2019-126218","article-title":"CD19-loss with preservation of other B cell lineage features in patients with large B cell lymphoma who relapsed post-axi-cel","volume":"134","author":"Neelapu","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2020.06.012_bib42","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1038\/nm.3838","article-title":"4-1BB costimulation ameliorates T\u00a0cell exhaustion induced by tonic signaling of chimeric antigen receptors","volume":"21","author":"Long","year":"2015","journal-title":"Nat Med"},{"key":"10.1016\/j.hoc.2020.06.012_bib43","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1038\/s41591-018-0201-9","article-title":"Induction of resistance to chimeric antigen receptor T\u00a0cell therapy by transduction of a single leukemic B cell","volume":"24","author":"Ruella","year":"2018","journal-title":"Nat Med"},{"key":"10.1016\/j.hoc.2020.06.012_bib44","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1158\/2159-8290.CD-15-1020","article-title":"Convergence of acquired mutations and alternative splicing of CD19 enables resistance to CART-19 immunotherapy","volume":"5","author":"Sotillo","year":"2015","journal-title":"Cancer Discov"},{"key":"10.1016\/j.hoc.2020.06.012_bib45","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1182\/blood-2019-122724","volume":"134","author":"Ardeshna","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2020.06.012_bib46","doi-asserted-by":"crossref","first-page":"4093","DOI":"10.1182\/blood-2019-126369","article-title":"A\u00a0phase 2, open-label, multicenter study evaluating the safety and efficacy of axicabtagene ciloleucel in combination with either rituximab or lenalidomide in patients with refractory large B-cell lymphoma (ZUMA-14)","volume":"134","author":"Neelapu","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2020.06.012_bib47","doi-asserted-by":"crossref","first-page":"TPS7585","DOI":"10.1200\/JCO.2018.36.15_suppl.TPS7585","article-title":"ZUMA-7: a phase 3 randomized trial of axicabtagene ciloleucel (Axi-Cel) versus standard-of-care (SOC) therapy in patients with relapsed\/refractory diffuse large B cell lymphoma (R\/R DLBCL)","volume":"36","author":"Oluwole","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2020.06.012_bib48","doi-asserted-by":"crossref","first-page":"7516","DOI":"10.1200\/JCO.2019.37.15_suppl.7516","article-title":"Safety and preliminary efficacy in patients (pts) with relapsed\/refractory (R\/R) mantle cell lymphoma (MCL) receiving lisocabtagene maraleucel (Liso-cel) in TRANSCEND NHL 001","volume":"37","author":"Wang","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2020.06.012_bib49","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1182\/blood-2019-127508","article-title":"Pivotal safety and efficacy results from transcend NHL 001, a multicenter phase 1 study of Lisocabtagene Maraleucel (liso-cel) in Relapsed\/Refractory (R\/R) large B cell lymphomas","volume":"134","author":"Abramson","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2020.06.012_bib50","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1182\/blood-2007-06-095331","article-title":"A\u00a0new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma","volume":"111","author":"Hoster","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2020.06.012_bib51","doi-asserted-by":"crossref","first-page":"802","DOI":"10.3109\/10428194.2013.815349","article-title":"Retrospective analysis of 235 unselected patients with mantle cell lymphoma confirms prognostic relevance of Mantle Cell Lymphoma International Prognostic Index and Ki-67 in the era of rituximab: long-term data from the Czech Lymphoma Project Database","volume":"55","author":"Salek","year":"2014","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.hoc.2020.06.012_bib52","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1200\/JCO.2015.63.8387","article-title":"Prognostic value of Ki-67 index, cytology, and growth pattern in mantle-cell lymphoma: results from randomized trials of the European Mantle Cell Lymphoma Network","volume":"34","author":"Hoster","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2020.06.012_bib53","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1182\/blood-2015-02-628792","article-title":"High-dose cytarabine does not overcome the adverse prognostic value of CDKN2A and TP53 deletions in mantle cell lymphoma","volume":"126","author":"Delfau-Larue","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2020.06.012_bib54","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1182\/blood-2017-04-779736","article-title":"TP53 mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy","volume":"130","author":"Eskelund","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2020.06.012_bib55","doi-asserted-by":"crossref","first-page":"3995","DOI":"10.1182\/blood-2019-123812","article-title":"High TP53 mutation load predicts primary refractory mantle cell lymphoma","volume":"134","author":"Obr","year":"2019","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.hoc.2020.06.012_bib56","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.3324\/haematol.2018.214056","article-title":"KMT2D mutations and TP53 disruptions are poor prognostic biomarkers in mantle cell lymphoma receiving high-dose therapy: a FIL study","volume":"105","author":"Ferrero","year":"2020","journal-title":"Haematologica"},{"key":"10.1016\/j.hoc.2020.06.012_bib57","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1182\/blood-2011-11-391474","article-title":"Whole transcriptome sequencing reveals recurrent NOTCH1 mutations in mantle cell lymphoma","volume":"119","author":"Kridel","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2020.06.012_bib58","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1038\/s41417-018-0022-5","article-title":"Genomic landscape and prognostic analysis of mantle cell lymphoma","volume":"25","author":"Yang","year":"2018","journal-title":"Cancer Gene Ther"},{"key":"10.1016\/j.hoc.2020.06.012_bib59","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1111\/bjh.12854","article-title":"SOX11 and TP53 add prognostic information to MIPI in a homogenously treated cohort of mantle cell lymphoma--a Nordic Lymphoma Group study","volume":"166","author":"Nordstrom","year":"2014","journal-title":"Br J Haematol"},{"key":"10.1016\/j.hoc.2020.06.012_bib60","doi-asserted-by":"crossref","first-page":"5307","DOI":"10.1158\/0008-5472.CAN-12-1615","article-title":"Molecular subsets of mantle cell lymphoma defined by the IGHV mutational status and SOX11 expression have distinct biologic and clinical features","volume":"72","author":"Navarro","year":"2012","journal-title":"Cancer Res"},{"key":"10.1016\/j.hoc.2020.06.012_bib61","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S1535-6108(03)00028-X","article-title":"The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma","volume":"3","author":"Rosenwald","year":"2003","journal-title":"Cancer Cell"},{"key":"10.1016\/j.hoc.2020.06.012_bib62","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1200\/JCO.2016.70.7901","article-title":"New molecular assay for the proliferation signature in mantle cell lymphoma applicable to formalin-fixed paraffin-embedded biopsies","volume":"35","author":"Scott","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2020.06.012_bib63","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1182\/blood-2018-03-838136","article-title":"A\u00a0gene signature that distinguishes conventional and leukemic nonnodal mantle cell lymphoma helps predict outcome","volume":"132","author":"Clot","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2020.06.012_bib64","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1016\/j.ccell.2016.09.014","article-title":"Decoding the DNA methylome of mantle cell lymphoma in the light of the entire B cell lineage","volume":"30","author":"Queiros","year":"2016","journal-title":"Cancer Cell"},{"key":"10.1016\/j.hoc.2020.06.012_bib65","doi-asserted-by":"crossref","first-page":"e109","DOI":"10.1016\/S2352-3026(18)30018-8","article-title":"Ibrutinib, lenalidomide, and rituximab in relapsed or refractory mantle cell lymphoma (PHILEMON): a multicentre, open-label, single-arm, phase 2 trial","volume":"5","author":"Jerkeman","year":"2018","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.hoc.2020.06.012_bib66","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1200\/JCO.2013.52.2466","article-title":"Confirmation of the mantle-cell lymphoma international prognostic index in randomized trials of the European Mantle-Cell Lymphoma Network","volume":"32","author":"Hoster","year":"2014","journal-title":"J\u00a0Clin Oncol"}],"container-title":["Hematology\/Oncology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858820300757?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858820300757?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T12:13:59Z","timestamp":1760184839000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889858820300757"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":66,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["S0889858820300757"],"URL":"https:\/\/doi.org\/10.1016\/j.hoc.2020.06.012","relation":{},"ISSN":["0889-8588"],"issn-type":[{"value":"0889-8588","type":"print"}],"subject":[],"published":{"date-parts":[[2020,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Key Clinical and Translational Research Questions to Address Unmet Needs in Mantle Cell Lymphoma","name":"articletitle","label":"Article Title"},{"value":"Hematology\/Oncology Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hoc.2020.06.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}